155 related articles for article (PubMed ID: 12170454)
1. P53 as a marker of differentiation between hyperplastic and adenomatous parathyroids.
Ricci F; Mingazzini PL; Sebastiani V; D'Erasmo E; Letizia C; De Toma G; Alò PL
Ann Diagn Pathol; 2002 Aug; 6(4):229-35. PubMed ID: 12170454
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical study of fatty acid synthase, Ki67, proliferating cell nuclear antigen, and p53 expression in hyperplastic parathyroids.
Alò PL; Visca P; Mazzaferro S; Serpieri DE; Mangoni A; Botti C; Monaco S; Carboni M; Zaraca F; Trombetta G; Di Tondo U
Ann Diagn Pathol; 1999 Oct; 3(5):287-93. PubMed ID: 10556475
[TBL] [Abstract][Full Text] [Related]
3. A histological comparison of adenomatous and hyperplastic parathyroid glands.
Lawrence DA
J Clin Pathol; 1978 Jul; 31(7):626-32. PubMed ID: 670416
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis and P53, Bcl-2 and Bax gene expression in parathyroid glands of patients with hyperparathyroidism.
Szende B; Farid P; Végso G; Perner F; Kopper L
Pathol Oncol Res; 2004; 10(2):98-103. PubMed ID: 15188026
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of p53 immunoexpression in parathyroid hyperplasias secondary to uremia, primary hyperplasias, adenomas and carcinomas.
Kayath MJ; Martin LC; Vieira JG; Roman LM; Nosé-Alberti V
Eur J Endocrinol; 1998 Jul; 139(1):78-83. PubMed ID: 9703382
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of laboratory findings in patients with primary hyperparathyroidism.
Mózes G; Curlee KJ; Rowland CM; van Heerden JA; Thompson GB; Grant CS; Farley DR
J Am Coll Surg; 2002 Feb; 194(2):126-30. PubMed ID: 11848628
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid glands in uraemic patients with refractory hyperparathyroidism: histopathology and p53 protein expression analysis.
Martin LN; Kayath MJ; Vieira JG; Nosé-Alberti V
Histopathology; 1998 Jul; 33(1):46-51. PubMed ID: 9726048
[TBL] [Abstract][Full Text] [Related]
8. Cox-2 expression in the oxyphilic cells of the normal, hyperplastic, and adenomatous parathyroid gland.
Bell CD; Vidal S; Kovacs K; Anderson J; Rotondo F
Endocr Pathol; 2004; 15(1):29-38. PubMed ID: 15067174
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid hormone content distinguishes true normal parathyroids from parathyroids of patients with primary hyperparathyroidism.
Weber CJ; Russell J; Chryssochoos JT; Hagler M; McGarity WC
World J Surg; 1996 Oct; 20(8):1010-4; discussion 1014-5. PubMed ID: 8798358
[TBL] [Abstract][Full Text] [Related]
10. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma.
Tominaga Y; Tsuzuki T; Uchida K; Haba T; Otsuka S; Ichimori T; Yamada K; Numano M; Tanaka Y; Takagi H
Kidney Int; 1999 Apr; 55(4):1375-83. PubMed ID: 10201002
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric DNA analysis of benign hyperfunctioning parathyroid glands: significant difference in the S phase fraction and proliferative index between adenomas and hyperplasias.
Berczi C; Bocsi J; Balázs G; Lukács G
Pathology; 2002 Oct; 34(5):442-5. PubMed ID: 12408343
[TBL] [Abstract][Full Text] [Related]
12. Chromogranin A and B in parathyroid tissue of cases of primary hyperparathyroidism: an immunohistochemical study.
Schmid KW; Hittmair A; Ladurner D; Sandbichler P; Gasser R; Tötsch M
Virchows Arch A Pathol Anat Histopathol; 1991; 418(4):295-9. PubMed ID: 2024450
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2, p53 and MIB-1 expression in normal and neoplastic parathyroid tissues.
Naccarato AG; Marcocci C; Miccoli P; Bonadio AG; Cianferotti L; Vignali E; Cipollini G; Viacava P
J Endocrinol Invest; 1998 Mar; 21(3):136-41. PubMed ID: 9591207
[TBL] [Abstract][Full Text] [Related]
14. [The use of flow cytometry in the study of parathyroid hyperplasia and adenomas].
Mangili F; Sassi I; Schiaffino E; Zogno C; Cantaboni A; Schmid C
Pathologica; 1992; 84(1092):459-65. PubMed ID: 1491887
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid hormone immunohistochemistry in dogs with primary and secondary hyperparathyroidism: the question of adenoma and primary hyperplasia.
van Vonderen IK; Kooistra HS; Peeters ME; Rijnberk A; van den Ingh TS
J Comp Pathol; 2003 Jul; 129(1):61-9. PubMed ID: 12859909
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of parathyroid hormone and chromogranin A in secondary hyperparathyroidism: a functional marker for secretory activity of hyperplastic nodules.
Tanaka R; Umemura S; Kakuta T; Fujisaki T; Sakai H; Saitoh A; Osamura RY
Pathol Res Pract; 2003; 199(2):93-9. PubMed ID: 12747471
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53, Ki-67 and Bcl-2 in parathyroid adenoma and residual normal tissue.
Hadar T; Shvero J; Yaniv E; Ram E; Shvili I; Koren R
Pathol Oncol Res; 2005; 11(1):45-9. PubMed ID: 15800682
[TBL] [Abstract][Full Text] [Related]
18. Adrenomedullin immunoreactivity tissue distribution in parathyroids of the patients with primary hyperparathyroidism.
Letizia C; Ricci F; De Toma G; Cianci R; Alo P; Celi M; Panzironi G; Mingazzini PL; D'Erasmo E; Mazzuoli GF
Horm Metab Res; 2004 Jul; 36(7):480-4. PubMed ID: 15305232
[TBL] [Abstract][Full Text] [Related]
19. [In vitro dynamics of parathyroid hormone secretion regulated by calcium and effects on the cell cycle: parathyroid hyperplasia versus adenoma].
Durán CE; Torregrosa JV; Canalejo A; Almadén Y; Campistol JM; Rodríguez Portillo M
Nefrologia; 2010; 30(4):413-9. PubMed ID: 20651882
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of Insulin-like growth factor-1, Transforming growth factor-beta1, and Vascular endothelial growth factor in parathyroid adenoma and hyperplasia.
Sayar H; Sahin M; Dogan PO; Karabulut S; Seringec N; Oguz A
Indian J Pathol Microbiol; 2014; 57(4):549-52. PubMed ID: 25308005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
